As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company Biogen, after rejecting their $469 million buy-out proposal late last ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since rejecting Biogen’s unsolicited acquisition offer. Sage Therapeutics Inc ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Biogen's strategic missteps, including the failed Sage Therapeutics acquisition, underscore a lack of innovation and direction, leading to a "sell" rating. Despite being forewarned, Wall Street ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

The reimbursement from Biogen to Sage for R&D expenses pursuant to the Sage/Biogen Collaboration and License Agreement was $1.3 million in the fourth quarter of 2024 compared to $8.3 million in ...

Sage Therapeutics and partner Biogen equally shares profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...